Day 56 is an early time-point, and the Company is hopeful for positive trends at Day 56, but the data at the 6-month time point will provide further insights to the DMOAD capabilities of the drug along with imaging data (MRI) and clinical effect data (pain and function).
With Day 56 being an early time-point, what this means is the biomarker data at Day 56 is less relevant to the DMOAD prospects than the data at 6-months, which will "provide further insights" by showing links between Biomarker data + MRI + pain and function. So even if the biomarker data is positive, it's important to temper your expectations and not think this equates to DMOAD activity.
Day 56 data from the PARA_OA_008 trial is currently being analysed by an independent clinical research organisation to then be prepared for market release.
This means PAR do not know the results yet.
Day 56 is an early time-point, and the Company is hopeful for...
-
- There are more pages in this discussion • 82 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add PAR (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
24.5¢ |
Change
-0.015(5.77%) |
Mkt cap ! $85.70M | |||
| Open | High | Low | Value | Volume |
| 26.0¢ | 26.0¢ | 24.5¢ | $265.4K | 1.050M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 8 | 130186 | 24.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 25.0¢ | 11571 | 1 |
View Market Depth
| Last trade - 16.10pm 31/07/2024 (20 minute delay) ? |
| PAR (ASX) Chart |